Evidence map›Paper›PMID 39881881›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2024

Function of formyl peptide receptor 2 in adriamycin resistance of breast cancer.

Landi Su, Jingjing Li, Li Qin, Yang Feng, Dingwen Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Landi SuSchool of Medicine, Yangzhou Polytechnic College, Yangzhou, Jiangsu, China.
Jingjing LiSchool of Medicine, Yangzhou Polytechnic College, Yangzhou, Jiangsu, China.
Li QinSchool of Medicine, Yangzhou Polytechnic College, Yangzhou, Jiangsu, China.
Yang FengSchool of Medicine, Yangzhou Polytechnic College, Yangzhou, Jiangsu, China.
Dingwen XuSchool of Medicine, Yangzhou Polytechnic College, Yangzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FPRL2 has been shown to be associated with a variety of tumours but has not been well studied in breast cancer. In this study, We combine molecular biology techniques with bioinformatics to analyze the role of FPRL2 in breast cancer and adriamycin resistance. By utilizing bioinformatics, we mine TCGA and GEO public databases to assess FPRL2 expression in breast cancer patients and its correlation with patient prognosis. Additionally, we employ the DepMap tool to probe the CCLE database, examining the relationship between FPRL2 gene effects and adriamycin sensitivity. Chemosensitivity of Adriamycin in breast cancer cells was tested by CCK-8 method. The apoptosis of breast cancer cells was determined by flow cytometry assay. Expression of p-ERK5 and p-AKT was determined by Western blot assay. Our results indicate that the expression level of FPRL2 in tumor tissues of breast cancer patients is significantly higher than that in normal tissues, and it correlates with poor prognosis in patients. Furthermore, the expression level of FPRL2 in tumor tissues of adriamycin-resistant breast cancer patients is also significantly higher than that in adriamycin-sensitive patients. The IC

Indexed as

Antibiotics, AntineoplasticBreast NeoplasmsDoxorubicinDrug Resistance, NeoplasmReceptors, Formyl PeptideReceptors, LipoxinApoptosisCell Line, TumorComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansPrognosisProto-Oncogene Proteins c-aktAntibiotics, AntineoplasticDoxorubicinFPR2 protein, humanProto-Oncogene Proteins c-aktReceptors, Formyl PeptideReceptors, Lipoxinadriamycin resistanceapoptosisbreast cancerFPRL2molecular docking

Identifiers

PMID39881881
PMCPMC11776488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.